Compare Illumina, Inc. (ILMN) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Liberty Global Ltd Class C — how do they compare? Illumina, Inc. trades at $191.8 (market cap $29.13B), while Liberty Global Ltd Class C trades at $10.14 (market cap $3.54B). The key difference: Illumina, Inc. is far larger — about 8.2× Liberty Global Ltd Class C's market cap, and Illumina, Inc. is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| ILMN | LBTYK | |
|---|---|---|
Market Cap | $29.13B | $3.54B |
Sector | Health | Technology |
52-Week High | $205.10 | $12.67 |
52-Week Low | $91.00 | $9.59 |
Enterprise Value | $30.49B | $10.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.57, up 0.4% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue remains stable around $4.3B, and profitability has improved significantly, with a net income margin of 19.57% in 2025. The company maintains robust cash flow from operations of $1.08B in 2025.
The outlook is mixed; strong fundamentals and analyst buy ratings support upside to the $201.58 consensus target, but technical weakness and high valuation ratios pose near-term risks. Key opportunities include sustained earnings beats and AI initiatives, while risks involve competitive pressures and execution challenges in a volatile market.
LBTYK trades at $10.13, up 1.4% on the day, amid a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses, while full-year 2025 showed a net loss of $7.14B despite $4.88B revenue. Positive cash flow trends and the upcoming Ziggo Group spin-off in 2027 are key developments, with analyst sentiment leaning bullish with 69% buy ratings.
The outlook hinges on execution of asset monetizations and the Ziggo listing, offering upside from a discounted valuation, but high losses and competitive pressures pose significant risks. Investors should weigh the sum-of-parts opportunity against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
